Join our daily newsletter At The Bell to receive exclusive market insights
- Alterity Therapeutics (ATH) has received a U.S. patent to trial treatments for neurodegenerative diseases, such as Alzheimer’s and Parkinson diseases
- The patent covers more than 150 types of treatments, which aim to readjust high iron levels in the brain related to neurodegenerative conditions
- The new patent will give the company 20 years of exclusivity and will support the expansion of Alterity’s drug development profile
- Additionally, the company is looking at patent protection in other jurisdictions
- On the market today, Alterity is up 26.9 per cent and is trading for 3.3 cents per share
Alterity Therapeutics (ATH) has received a U.S. patent for its next-generation compounds to treat neurodegenerative diseases.
The patent was given the tick of approval by the United States Patent and Trademark Office (USPTO).
Neurodegenerative diseases are a group of disorders that impact the central nervous system or the peripheral nervous systems. Common diseases include Alzheimer’s and Parkinson.
The patent, dubbed “Compounds for and Methods of Treating Diseases,” covers more than 150 pharmaceutical compositions that are designed to readjust high iron levels related to Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions.
Alterity is looking into treatments that can combat high levels of iron in the brain.
The new patent will give the company 20 years of exclusivity and support the expansion of Alterity’s drug development profile.
Currently, Alterity’s lead product, ATH434, is currently in clinical development and is showing positive signs.
Chairman and CEO, Geoffrey Kempler, says this patent creates a strong foundation for the company to pursue a range of treatments across multiple neurodegenerative diseases.
“There is a growing clinical and scientific focus on the implication of elevated iron in the brain of people with neurodegenerative disease. Alterity has been at the forefront of research and drug development in this area, and we have significant research to support our current and future drug development efforts,” he said.
“This patent allows us to fully prosecute these opportunities with confidence in the coming years to address some of the most devasting brain diseases which currently have few or no treatment options,” he added.
Additionally, the company is looking at patent protection in other jurisdictions.
On the market today, Alterity is up 26.9 per cent and is trading for 3.3 cents per share at 10:23 am AEDT.
